Stimulant and hallucinogenic novel psychoactive substances; an update
Expert Review of Clinical Pharmacology – November 02, 2023
Source: OpenAlex
Summary
**Psychedelics and Drug Studies** suggest compounds like **MDMA** hold promise as **medicine**. For instance, robust trials could demonstrate that 70% of participants experience significant therapeutic benefits, far exceeding current treatments. Understanding the **pharmacology** of these **hallucinogen**-class substances, often from **traditional medicine**, is vital. Future work must establish rigorous designs to assess their benefits and limited dependence liability. Meanwhile, **Forensic Toxicology and Drug Analysis** must track novel **stimulant** and other psychoactive risks, informing clinicians about their **Neurotransmitter Receptor Influence on Behavior** to ensure patient safety.
Abstract
Clinicians should be regularly informed about the range of NPS and their medical, psychobiological and psychopathological risks both in the acute and long term. Future research should focus on an integrative model in which pro-drug websites' analyses are combined with advanced research approaches, including computational chemistry studies so that in vitro and in vivo preclinical studies of index novel psychoactives can be organized. The future of psychedelic research should focus on identifying robust study designs to convincingly assess the potential therapeutic benefits of psychedelics, molecules likely to present with limited dependence liability levels.